Race presents at IRD Invest

preview_player
Показать описание
Dr Daniel Tillett, COO, Race Oncology Limited (ASX: RAC) presents at IRD Invest the inaugural virtual investor conference of IR Department.

Race Oncology is a specialty pharmaceutical company whose business model is to pursue later stage drug assets, principally in the cancer field. It has a Phase II/III cancer drug called Bisantrene which it is developing for acute myeloid leukaemia (AML) as well as breast and ovarian cancer.
Рекомендации по теме